Primary and metastatic peritoneal surface malignancies.

Details

Ressource 1Download: s41572-021-00326-6.pdf (3142.91 [Ko])
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_99C98AEC54C0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Primary and metastatic peritoneal surface malignancies.
Journal
Nature reviews. Disease primers
Author(s)
Cortés-Guiral D., Hübner M., Alyami M., Bhatt A., Ceelen W., Glehen O., Lordick F., Ramsay R., Sgarbura O., Van Der Speeten K., Turaga K.K., Chand M.
ISSN
2056-676X (Electronic)
ISSN-L
2056-676X
Publication state
Published
Issued date
16/12/2021
Peer-reviewed
Oui
Volume
7
Number
1
Pages
91
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
Peritoneal surface malignancies comprise a heterogeneous group of primary tumours, including peritoneal mesothelioma, and peritoneal metastases of other tumours, including ovarian, gastric, colorectal, appendicular or pancreatic cancers. The pathophysiology of peritoneal malignancy is complex and not fully understood. The two main hypotheses are the transformation of mesothelial cells (peritoneal primary tumour) and shedding of cells from a primary tumour with implantation of cells in the peritoneal cavity (peritoneal metastasis). Diagnosis is challenging and often requires modern imaging and interventional techniques, including surgical exploration. In the past decade, new treatments and multimodal strategies helped to improve patient survival and quality of life and the premise that peritoneal malignancies are fatal diseases has been dismissed as management strategies, including complete cytoreductive surgery embedded in perioperative systemic chemotherapy, can provide cure in selected patients. Furthermore, intraperitoneal chemotherapy has become an important part of combination treatments. Improving locoregional treatment delivery to enhance penetration to tumour nodules and reduce systemic uptake is one of the most active research areas. The current main challenges involve not only offering the best treatment option and developing intraperitoneal therapies that are equivalent to current systemic therapies but also defining the optimal treatment sequence according to primary tumour, disease extent and patient preferences. New imaging modalities, less invasive surgery, nanomedicines and targeted therapies are the basis for a new era of intraperitoneal therapy and are beginning to show encouraging outcomes.
Pubmed
Web of science
Open Access
Yes
Create date
05/01/2022 16:40
Last modification date
12/01/2022 7:35
Usage data